Cargando…
1114. Comparative analysis between Polymerized Type I Collagen and Baricitinib as potential treatment for COVID-19
BACKGROUND: Baricitinib is a treatment authorized by the FDA for the treatment of moderate to severe COVID-19, despite this there are few approved drugs; polymerized type I collagen (PTIC) is a drug that has been used in Mexico with great potential for treating moderate to severe cases of COVID-19....
Autores principales: | Carpio-Orantes, Luis Del, García-Mendez, Sergio, Sánchez-Díaz, Jesús Salvador, Aguilar-Silva, Andrés, García-Hernández, Omar, Salazar-Lizárraga, Raúl Enrique, González-Arce, América Alejandrina, Martínez-Rojas, Manuel, Jiménez-Flores, Oscar Rodrigo, Villalobos-López, Luis Roberto, Hernández-Gómez, Héctor Nahín, Domínguez-Cámara, Rubén |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752297/ http://dx.doi.org/10.1093/ofid/ofac492.953 |
Ejemplares similares
-
520. Polymerized type I collagen as a treatment for COVID-19 in Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2023) -
498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021) -
396. Clinical Characterization of Long COVID in Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2023) -
Afeccion de los procesos mentales en estudiantes fumadores de la Facultad de Medicina Miguel Aleman Valdes.: /
por: González Arce, América Alejandrina
Publicado: (2013) -
Anosmia and dysgeusia as markers of severity and prognosis in COVID-19
por: Carpio-Orantes, Luis Del, et al.
Publicado: (2023)